What Patients Should Ask After a Surrogate Endpoint Headline

The quiet word in the headline

A drug story says a treatment "worked." Read the next line and you often find the trial did not measure how long people lived. It measured something else, and something faster. That something is a surrogate endpoint.

An endpoint is the outcome a trial is built to measure. The National Cancer Institute defines it as an event or outcome that can be measured objectively to decide whether a treatment helps. Survival, symptom relief, quality of life, and tumor disappearance are all endpoints.

A surrogate endpoint is a stand-in. NCI defines it as an indicator used in place of another to tell if a treatment works. A shrinking tumor is one. A falling biomarker level in the blood is another. They are used instead of stronger measures, such as living longer or feeling better, because the trial can be finished sooner.

NCI ends that definition with a warning that headlines rarely carry. Surrogate endpoints are not always true indicators of how well a treatment works.

The endpoints you will meet

• Overall survival, or OS. How long people live from diagnosis or from the start of treatment. This is the hardest to argue with and the slowest to collect.
• Progression-free survival, or PFS. How long a person lives with the disease without it getting worse. Worse is defined by scan measurements and rules set before the trial starts.
• Objective response rate, or ORR. The share of people whose tumors shrank or vanished within a set window.
• Disease-free survival, or DFS. After treatment for early-stage disease ends, how long a person goes with no sign of the cancer returning.

Only the first counts deaths. The rest count events on a scan or a lab sheet. Our page on complete and partial response covers how those tumor categories are assigned.

Why the FDA allows a stand-in

This is not sloppiness. It is policy, and it has a date.

In 1992 the FDA created its Accelerated Approval pathway. It lets drugs for serious conditions with unmet need be approved on a surrogate endpoint. In 2012, Congress extended this so approval could also rest on an intermediate clinical endpoint.

The FDA describes a surrogate used this way as a marker. It can be a lab measurement, an image, or a physical sign that is thought to predict clinical benefit but is not itself a measure of benefit. The agency's own example is blunt: rather than wait to learn whether a drug extends survival, it may approve based on evidence that the drug shrinks tumors, because shrinkage is considered reasonably likely to predict real benefit.

Reasonably likely is not the same as proven. That is the whole trade. Speed now, certainty later.

Where the stand-in can fail

A tumor can shrink without the person living longer. A biomarker can fall while the disease keeps moving. Three specific gaps are worth holding in mind.

The first is timing. A trial that measures PFS may stop counting long before it knows anything about survival. The second is measurement. Progression is declared by rules about scan dimensions, and those rules can be checked on different schedules in the two arms of a trial. The third is harm. A drug can delay progression on film while causing side effects heavy enough to erase the gain in daily life.

The FDA keeps a public table of surrogate endpoints that have been the basis of drug approval. It is a useful reminder that a surrogate is a specific, named, argued-over thing, not a general claim.

Reading a specific headline

Five questions get you most of the way.

1. What was measured? Look for OS, PFS, ORR, or DFS by name.
2. How big was the gap? A difference of a few weeks in median PFS is a different story from a year.
3. Compared with what? A trial against placebo answers a smaller question than one against current standard care.
4. Who was in it? Stage, prior treatments, age range, and biomarker status all narrow who the result applies to.
5. Was survival reported at all, even as a secondary result trending one way?

Our guides to what clinical trials are and how a trial compares with standard treatment go through the trial design side of this.

When to call your team

Scan schedules and trial endpoints run on their own calendar. Your symptoms do not. During cancer treatment, contact the care team the same day for:

• A fever of 100.4 degrees Fahrenheit, or 38 degrees Celsius, or higher
• Shaking chills, with or without a fever
• A new cough, sore throat, or shortness of breath
• Redness, swelling, or pain where a catheter or port enters the skin
• Bloody or cloudy urine, or pain when passing urine
• Sores or white coating in the mouth
• Diarrhea that does not stop

Infection during treatment can become life threatening quickly. NCI also advises checking with the team before taking acetaminophen or ibuprofen for a fever, because those drugs can mask a serious problem.

What a headline cannot settle

A trial result describes an average across a group that met the entry rules. It does not describe one person, and it does not weigh what a given person is willing to trade. Two people reading the same PFS number can reach different, reasonable conclusions about whether the drug is worth its side effects.

The useful move after a surrogate endpoint headline is to name the endpoint out loud, find the size of the effect, and check whether the trial population looks like your situation. If you are considering a trial, our list of questions to ask about a clinical trial covers the rest.

Sources

• NCI Dictionary of Cancer Terms, surrogate endpoint — https://webapis.cancer.gov/glossary/v1/Terms/Cancer.gov/Patient/en/surrogate-endpoint
• NCI Dictionary of Cancer Terms, progression-free survival — https://webapis.cancer.gov/glossary/v1/Terms/Cancer.gov/Patient/en/progression-free-survival
• NCI Dictionary of Cancer Terms, overall survival — https://webapis.cancer.gov/glossary/v1/Terms/Cancer.gov/Patient/en/overall-survival
• NCI Dictionary of Cancer Terms, objective response rate — https://webapis.cancer.gov/glossary/v1/Terms/Cancer.gov/Patient/en/objective-response-rate
• FDA, Accelerated Approval — https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval
• FDA, Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure — https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
• NCI, Infection and Neutropenia during Cancer Treatment — https://www.cancer.gov/about-cancer/treatment/side-effects/infection
• NCI, Clinical Trials Information for Patients and Caregivers — https://www.cancer.gov/research/participate/clinical-trials